PRINCETON, N.J. & GURGAON, India--(BUSINESS WIRE)--Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL, NSE: RANBAXY, BSE: 500359) (“Ranbaxy”), has launched an authorized generic version of Caduet® in the U.S. market, as part of an agreement with Pfizer Inc.
